USPTO serial 97661016
PI-VIEW
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 30, 2025
- Examiner
- WHELAN, JAIME M
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PI-VIEW?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hun Joon Kim
Hun Joon Kim LEX IP MEISTER, PLLC.5160 Parkstone Drive, Suite 140CHANTILLY, VA 20151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Biochip for research or scientific purposes; Biochip sensors for research or scientific purposes; Cell chip inspection devices, namely, bio-cell chips for research or scientific purposes; DNA chip; DNA analysis apparatus, namely, scientific apparatus for DNA purification and analysis; DNA sequencing devices, namely, scientific apparatus and instruments for sequencing DNA; Diagnostic apparatus for the detection of biomarkers for laboratory or research use; Protein analysis devices, namely, scientific apparatus and instruments for analyzing protein; Protein sequencing devices, namely, scientific apparatus and instruments for sequencing protein; Laboratory apparatus for analyzing biological pharmaceuticals; Scientific instruments for analyzing chemical and biological substances for the presence, absence, or quantity of target biologics and chemicals; Optical imaging apparatus and instruments for use in the study of proteins, peptides, DNA, aptamer, and RNA, not for medical purposes; Spectroscopes; Microscopes and parts thereof; Optical scanner; optical measurement components for biological industrial and research use; Computer storage devices, namely, high-speed storage subsystems for storage of optical images and measurement records; Biosensors, namely, sensors for the purpose of scientific and diagnostic use for detecting the presence of multiple molecular substances; Diagnostic apparatus for the detection of proteins, DNA, and cells, not for medical purpose; Downloadable images in the field of in vitro diagnostics, namely fluorescence images used for in vitro diagnostics; Analyzers for analyzing immunological activity for scientific purposes *none of the foregoing for use in the mammography field or relating to the medical imaging of the breast* | ACTIVE | — |
| 010 | Analyzers for analyzing immunological activity for medical purposes; Medical apparatus and instrument for diagnostic use, namely, for medical diagnostic testing in the fields of cell-based testing; [ Medical diagnostic apparatus for detecting cancer; ] Medical diagnostic apparatus for analyzing drug compounds; Immunoassay apparatus for detecting and analyzing biomarkers for medical diagnoses; Medical diagnostic apparatus for testing genomic materials, proteins, and cells relevant to diseases; Medical instruments for analyzing and identifying genomic materials, proteins, and cells; Medical diagnostic apparatus and instruments for detecting and analyzing diseases related to genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals; [ Medical imaging apparatus; ] Diagnostic measuring apparatus for medical use by analyzing genomic materials, proteins and cells; Apparatus for medical, clinical, and diagnostic uses by analyzing genomic materials, proteins, and cells related to genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals; Computer displays and computer monitors and controllers used in direct association with medical diagnosis apparatuses during the process of diagnosis of a condition, namely genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals in an individual; Immunochemical testing apparatus for analyzing genomic materials, proteins, and cells for medical use; Automatic analyzers for disease diagnosis through inspection of genomic materials, proteins, and bio-samples for medical purposes; Apparatus for testing genomic materials, proteins, and cells relevant to diseases for medical purposes; [ Apparatus for tumor diagnosis; ] Medical apparatus for testing genomic materials, proteins, and cells relevant to diseases, namely the cancer and inflammatory disease; Apparatus for analyzing images for medical use, namely, fluorescence imaging apparatus for medical purpose; Medical diagnostic apparatus for analyzing and measuring genomic materials, proteins, and bio-samples; In vitro medical diagnostic devices for molecularly characterizing diseases related to genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals *; none of the foregoing for use in the mammography field or relating to the medical imaging of the breast* | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Proteina Co., Ltd.
- Other trademarks owned by Proteina Co., Ltd.
- Other trademarks owned by Proteina Co., Ltd.
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named PI-VIEW
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| May 14, 2026 | XXXX | POST REGISTRATION ACTION CORRECTION | — |
| May 13, 2026 | WDRL | OTQR WITHDRAWAL FROM PUBLICATION | — |
| Mar 16, 2026 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Mar 9, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 9, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Sep 30, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 30, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 4, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Mar 26, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 5, 2025 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 4, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 6, 2025 | ALIE | ASSIGNED TO LIE | — |
| Nov 27, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 25, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 29, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 1, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 1, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 1, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 14, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 14, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 14, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 21, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 21, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 15, 2022 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Nov 15, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Nov 7, 2022 | NWAP | NEW APPLICATION ENTERED | — |